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ABSTRACT 
We present the case of a 42-year-old man affected by 
psoriasis with Staphylococcus Haemolyticus superin-
fection of Legionella pneumonia during infliximab 
therapy. The introduction of compounds that block 
TNF-α has yielded great benefits for patients affected 
by selected autoimmune diseases that fail to respond 
to classic anti-inflammatory agents, but, on the other 
hand, has led to an increased susceptibility to infec-
tions, in particular of those caused by intracellular 
pathogens, such as L. Pneumophila. Emerging evi-
dence suggests that legionellosis can be complicated 
by superinfection with other agents, including sap-
rophytic microorganisms, among which coagulase- 
negative staphylococci. To our knowledge, this is the 
first report of systemic legionellosis with superinfec-
tion by S. Haemolyticus, an emerging nosocomial 
multi-resistant pathogen that commonly causes sep-
ticemia, osteomyelitis or endocarditis, but has not so 
far been associated with necrotizing pneumonia. De-
spite the optimal antimicrobial therapy for Staphylo-
coccus spp. Pneumonia is still controversial, evidence 
suggests that in patients with confirmed positivity for 
methicillin resistant strains, particularly if sensitivity 
to vancomycin is suboptimal, linezolid should be the 
first choice therapy, being superior to vancomycin 
and teicoplanin. 
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1. INTRODUCTION 
On September 2010, a 42-year-old man presented to the 
emergency department because of fever, productive 
cough, and chest pain. He had a history of psoriasis, pre-
viously treated with acitretine 25 mg, which was discon-
tinued because of dyslipidemia. Nine months before the 
current admission he required hospitalization for 
erythrodermic psoriasis. Since then, he was treated with 
infliximab, and received the eighth infusion one week 
before presentation. Due to the incomplete control of 
disease activity, he was concurrently started on meth-
otrexate (10 mg s.c.). Five days before admission he 
reported the abrupt onset of fever which reached 39˚C, 
dry cough, asthenia, and burning pain in the right sub-
scapular region, which were unresponsive to aceta-
minophen and amoxicillin-clavulanate. 
On admission the temperature was 39.5˚C, blood 
pressure 125⁄80 mmHg, pulse 115, respiratory rate 24, 
peripheral oxygen saturation 98% while he was breath-
ing ambient air. Clinical examination revealed bilateral 
latero-cervical lymph nodes (soft, non-tender, and mo-
bile, < 2 cm), regular heart activity, slight rales at the left 
lower lobe, and splenomegaly. An electrocardiogram 
showed sinus tachycardia without alterations of the ST 
tract; biochemical test are shown in Table 1. Chest Rx 
showed a right middle lobe infiltrate (Figure 1(a)). Ab-
dominal ultrasonography was only notable for spleno- 
megaly (153 mm). Oxygen supplementation and hydra-
tion were provided. 
Microbiological analyses of blood were repeatedly 
negative and sputum was negative for M. tuberculosis 
and other microorganisms; L. Pneumophila serotype 1 
antigen was detected in urine samples. Intravenous 
levofloxacin 750 mg/day was started with improvement 
in systemic symptoms, and correction within 5 days of 
the alterations of creatine-phosphokinase levels, and 
hyponatremia, (Table 1). Because of the persistence of 
unremitting fever (> 38˚C), and increased inflammatory 
markers, azithromycin 500 mg/day was added on day 5. 
Blood cultures remained negative, as well as autoimmu-
nity markers. 
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One week after admission, the patient underwent a 
chest computed tomography (CT) scan showing upper 
and middle right lobe extensive infiltrate with an aerial 
bronchogram and patchy ground-glass infiltrates in the 
upper left lobe, minimal pleural and pericardial effusions 
and multiple bilateral supraclavicular, paratracheal, un-
dercarinal, and axillary lymphoadenopathies (up to 1.5 
cm). On day 8 Staphylococcus Haemolyticus was iso-
lated from the sputum, but initially interpreted as a con-
taminant (supplementary Table 1). A bronchoscopy was 
performed on day 10: the airways appeared normal and 
cytologic examination of bronchoalveolar-lavage (BAL) 
specimens of the right lobes revealed acute inflammation, 
but not malignant cells. Tests were negative for M. Tu-
bercolosis, Aspergillus spp, P. Jirovecii, Epstein-Barr 
Virus, Cytomegalovirus, Respiratory Syncythial virus 
multiplex PCR, whereas a nested PCR-based assay con-
firmed the positivity for L. Pneumophila. 
Broad-spectrum empirical antimicrobical therapy was 
started including piperacillin-tazobactam and imipenem 
(day 10); while clindamycin 600 mg t.i.d. i.v. was added 
on day 14 according to the S. Haemolyticus antibiogram 
(supplementary table), without benefit. 
On day 15 a CT scan was repeated, which showed the 
progression of the right pulmonary infiltrate with areas 
of colliquation and excavation (Figure 1(b)). Rifampicin 
replaced previous empirical therapy on day 17 because 
of the reported synergic effect with fluoroquinolones, 
and macrolides in the treatment of resistant legionellosis 
in immunosuppressed patients [1]. 
To exclude an immunosuppression related lymphomas, 
laterocervical lymph node biopsy was performed, which 
showed a reactive inflammatory pattern. A positron 
emission tomography CT scan showed inflammation in 
the right upper and lower pulmonary lobes and in the 
mediastinal lymph nodes. 
Several reports highlited an increased risk of infection 
by atypical pathogens associated with infliximab, in-
cluding M. Tubercolosis, Listeria, Pneumococcus, Le-
gionella, Salmonella, and Bartonella spp.), fungi, and 
viruses [2]. Although the patient chest Rx and protein 
purified derivative intradermoreaction were negative 
before starting infliximab and BAL was PCR negative 
for M.Tubercolosis, a quantiferon test for Mycobacte-
rium was performed, but it confirmed negativity for 
M.Tubercolosis. An echocardiogram was carried out on 
day 21, with no evidence of endocarditis. 
To exclude a pulmonary superinfection, a CT-guided 
needle-aspiration of the pulmonary lesion was per-
formed, with isolation of rare colonies of S. Haemo-
lyticus (supplementary Table 1). Vancomycin (minimal 
inhibitory concentration (MIC): 1) was started i.v. (day 
22) without response. In view of the sub-optimal MIC, 
incomplete pulmonary diffusion of vancomycin, and 
the relatively low plasma concentration achieved after 
treatment titration (12.5 µg/mL), linezolid (600 mg td 
i.v.) was introduced on day 33, with immediate remis-
sion of fever and normalization of inflammatory indi-
ces (Table 1). The patient was discharged on day 45. A 
chest CT scan after 4 weeks demonstrated resolution of 
the inflammatory infiltrates and a reduction of the ex-
cavated areas. 
This case is notable for several aspects. The introduc-
tion into clinical practice of compounds that block 
TNF-α has yielded great benefits for patients affected by 
selected autoimmune diseases that fail to respond to 
classic anti-inflammatory agents, but, on the other hand, 
has led to an increased susceptibility to infections [3], in 
particular of those caused by intracellular pathogens [4], 
and L. Pneumophila pneumonia has been reported as a 
life-threatening infection that frequently complicates 
anti-TNF-α therapy [3]. In line with our experience, 
evidence is accumulating that legionellosis, particularly 
in patients under immunosuppressive therapy, can be 
complicated by superinfection with other agents, includ-
ing saprophytic microorganisms. Furthermore, positivity 
for Legionella DNA may persist despite appropriate 
treatment in immunocompromised patients, and lung 
colliquative necrosis supports a diagnosis of coinfection 
with other bacterial agents. To our knowledge, this is the 
first report of systemic legionellosis with superinfection 
by S. Haemolyticus, an emerging nosocomial multire-
sistant pathogen that commonly causes septicemia, os-
teomyelitis or endocarditis, but has not so far been asso-
ciated with necrotizing pneumonia [5]. 
Finally, despite the optimal antimicrobial therapy for 
Staphylococcus spp. pneumonia is still controversial, 
evidence suggests that in cases with confirmed positivity 
 
 
(a)                         (b) 
Figure 1. (a) Chest X-ray on admission: right middle lobe 
infiltrate and left mild perihilar infiltrate; (b) Chest CT scan 
(day 15): upper right lobe extensive infiltrate with areas of 
colliquation and excavation (arrowheads) and patchy ground- 
glass infiltrates in the upper right lobe (arrows). 
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Table 1. Laboratory data. 
Hb: hemoglobin; WBC: white blood cells; CRP: C reactive protein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CPK: creatine phos-
phokinase; LDH: lactate dehydrogenase; PT: prothrombin time; aPTT: activated partial thromboplastin time; BE: base excess, na: not available. 
 
for methicillin resistant strains, particularly if sensitivity 
to vancomycin is suboptimal as in our case, linezolid 
might be superior to vancomycin and teicoplanin be-
cause of the better penetration into lung allowing to 
reach sustained concentrations above the MIC. 
In conclusion, clinicians should be aware of the in-
creased risk of severe and difficult-to-treat infections by 
atypical and saprophytic pathogens in the increasing 
number of patients treated anti-TNF-α agents. Among 
them, S. Haemolyticus is an emergent nosocomial 
pathogen, which may be associated with necrotizing 
pneumonia. Long-term follow-up and systematic as-
sessment of infective episodes may help to better define 
the clinical risk carried by anti-TNF-α agents in every-
day clinical practice, and possibly to identify risk factors 
for these complications. 
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 Reference Admission Day 5 Day 22 Day 33 Discharge (day 45) 
Hb (g/dl) 13.5 - 17.5 14.8 11.3 9.5 9.1 9.6 
WBCs (µl) 4.8 - 10.8 15250 12720 8090 4560 6390 
Neutrophils % - 91 77 68 73 59 
CRP (mg/dl) < 0.5 67.05 16.89 4.80 8.14 0.81 
Procalcitonin (ng/mL) 0.02 - 0.06 17.16 na 0.06 0.18 0.08 
AST (UI/ml) 5 - 38 80 81 24 17 21 
ALT (UI/ml) 5 - 41 33 68 25 14 13 
CPK (UI/ml) 38 - 174 1806 1065 16 15 16 
LDH (UI/ml) 240 - 480 1076 691 307 341 256 
PT ratio 0.89 - 1.16 1.3 1.24 1.23 1.2 1.07 
aPTT ratio 0.85 - 1.18 1.38 1.06 1.12 1.15 1.10 
Creatinine (mg/dL) 0.50 - 1.20 0.82 0.48 0.5 0.60 0.73 
Na+ (mEq/L) 135 - 145 125 140 140 141 142 
K+ (mEq/L) 3.30 - 5.10 3.6 4.1 4 3.1 4.3 
Cl– (mEq/L) 96 - 108 90 103 101 101 104 
TSH (mIU/mL) 0.280 - 4.300 4.07 na na na na 
pH 7.35 - 7.45 7.51 na 7.54 na 7.53 
pO2 (mmHg) 83 - 108 72 na 78 na 102 
pCO2 (mmHg) 32 - 48 26 na 28 na 36 
HCO3– (mEq/L) 24 - 26 24 na 23.9 na 30 
Lactate mEq/L 0.5 - 2.0 1.5 na 1.2 na 1.4 
BE –2 - +2 –2.3 na 1.9 na 7.4 
